An azumamide C analogue without the zinc-binding functionality by Villadsen, Jesper et al.
  
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
  
General rights 
Copyright and moral rights for the publications made accessible in the public portal are retained by the authors and/or other copyright owners 
and it is a condition of accessing publications that users recognise and abide by the legal requirements associated with these rights. 
 
• Users may download and print one copy of any publication from the public portal for the purpose of private study or research. 
• You may not further distribute the material or use it for any profit-making activity or commercial gain 
• You may freely distribute the URL identifying the publication in the public portal  
 
If you believe that this document breaches copyright please contact us providing details, and we will remove access to the work immediately 
and investigate your claim. 
   
 
Downloaded from orbit.dtu.dk on: Dec 20, 2017
An azumamide C analogue without the zinc-binding functionality
Villadsen, Jesper; Kitir, Betül; Wich, Kathrine; Friis, Tina; Madsen, Andreas Stahl; Olsen, Christian Adam
Published in:
MedChemComm
Link to article, DOI:
10.1039/C4MD00252K
Publication date:
2014
Document Version
Publisher's PDF, also known as Version of record
Link back to DTU Orbit
Citation (APA):
Villadsen, J., Kitir, B., Wich, K., Friis, T., Madsen, A. S., & Olsen, C. A. (2014). An azumamide C analogue
without the zinc-binding functionality. MedChemComm, 5, 1849-1855. DOI: 10.1039/C4MD00252K
An azumamide C analogue without
the zinc-binding functionality†
Jesper S. Villadsen,a Betu¨l Kitir,‡a Kathrine Wich,‡ Tina Friis,b Andreas S. Madsen‡a
and Christian A. Olsen‡*a
Histone deacetylase (HDAC) inhibitors have attracted considerable attention due to their promise as
therapeutic agents. Most HDAC inhibitors adhere to a general “cap-linker-Zn2+-binding group”
architecture but recent studies have indicated that potent inhibition may be achieved without a Zn2+-
coordinating moiety. Herein, we describe the synthesis of an azumamide analogue lacking its native
Zn2+-binding group and evaluation of its inhibitory activity against recombinant human HDAC1–11.
Furthermore, kinetic investigation of the inhibitory mechanism of both parent natural product and
synthetic analogue against HDAC3-NCoR2 is reported as well as their activity against Burkitt's lymphoma
cell proliferation.
Introduction
Histone deacetylase (HDAC) enzymes,1,2 or perhaps more
appropriately termed lysine deacylases (KDACs),3–5 have attrac-
ted attention as putative therapeutic targets,6–9 especially due to
their ability to modify the landscape of post-translational
modications (PTMs) on histone proteins in chromatin.6
Indeed, two HDAC inhibitors [i.e., SAHA (vorinostat, marketed
as Zolinza®)10 and romidepsin (FK228, marketed as Istodax®)11]
have received approval by the Food and Drug Administration in
the US for treatment of cutaneous T-cell lymphoma, and several
other compounds are currently in clinical trials for additional
indications.12
In addition to the depsipeptide romidepsin mentioned
above, Nature has provided a variety of potent macrocyclic
HDAC inhibitors such as the trapoxins, apicidins, azumamides,
chlamydocin, and largazole.13–15 The apicidin structure (1)16 has
been the subject of numerous structure–activity relationship
studies,17–23 and recently, analogues without the so-called Zn2+-
binding group (the ethylketone moiety) were investigated by
Ghadiri and coworkers (e.g., 2 and 3, Scheme 1).24 The Zn2+-
binding side chain was substituted with various alkyl groups,
and the optimal side chain at this position was a non-branched
propyl group. Not surprisingly, these inhibitors were signi-
cantly less potent than their ethylketone-containing counter-
parts, but still exhibited Ki-values of just 30–50 nM against
HDACs 1–3.24 Since a wide variety of enzymes rely on metal ions
for catalytic activity, excision of the Zn2+-binding group may
enable development of more selective HDAC inhibitors with
fewer adverse eﬀects.
We found this idea attractive and decided to investigate the
macrocyclic core of the azumamides25–27 (4–8) in a similar
fashion by synthesizing compound 9 (Scheme 1). The azuma-
mides contain relatively weak Zn2+-binding groups (carboxylate
or carboxyamide)28 while still exhibiting high potency as class I
HDAC inhibitors with low nanomolar Ki-values recorded for
Scheme 1 Structures of cyclic peptide HDAC inhibitors. Arrows show
the opposite N/ C directionality of apicidin and azumamide.
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azumamides C (6) and E (8).29 Since azumamide C was slightly
more potent than azumamide E, we substituted the Zn2+-
binding side chain of the b-amino acid in compound 6 with a
propyl group to give compound 9. In addition to removal of the
metal-coordinating capability, removal of this negatively
charged carboxylate, may furthermore improve cell perme-
ability of the ligand. We here present the synthesis and evalu-
ation of compound 9 as an HDAC inhibitor.
Results and discussion
Chemistry
The three D-amino acids necessary to prepare compound 9 were
purchased and the b-amino acid building block (14, Scheme 2)
was prepared using chiral sulnylimine 12, which was obtained
by condensation of butanal (10) and (S)-2-methylpropane-2-
sulnamide (“Ellman's auxiliary”, 11).30,31 The diastereo-
selective Mannich reaction between imine (12) and the Z-eno-
late of tert-butyl propionate provided the (2S,3R)-b-amino ester
(13) as the major diastereoisomer. Acid mediated cleavage of
the tert-butyl ester and the sulnyl group with both TFA andHCl
to ensure full conversion, aﬀorded the fully deprotected b-
amino acid and subsequent treatment with Fmoc-OSu fur-
nished the desired b-amino acid building block (14).
Unfortunately, we were unable to obtain crystals for deter-
mination of the absolute stereochemistry by X-ray crystallog-
raphy. Thus, the stereochemistry was instead conrmed by
conversion of sulnyl-protected tert-butyl ester 13 to the previ-
ously reported Cbz-protected methyl ester (15, Scheme 3) and
both optical rotation and NMR data were in full agreement with
the previously reported data32 (see also ESI, Table S1†).
Coupling of the b-amino acid (14) to a resin-bound tripeptide
[H–D-Val–D-Ala–D-Tyr–(2-chlorotrityl-resin)] using HATU, fol-
lowed by removal of the Fmoc group and cleavage from the resin
aﬀorded linear tetrapeptide 16. Macrolactamization, under
dilute conditions (0.4 mM in DMF), using HATU as the coupling
reagent aﬀorded target peptide 9 (Scheme 4). The relatively low
yield is similar to those previously achieved for similar
compounds21–24 and may, at least in part, be attributed to poor
solubility in the water–acetonitrile mobile phase used in
reversed-phase HPLC purication. However, further optimiza-
tion of cyclization eﬃciency, which is known to be notoriously
troublesome for small peptides,33 may also prove worthwhile.
Proling of HDAC inhibitory activity
We rst screened the new compound along with a non-cyclized
azumamide C analogue (for structure, see ESI, Fig. S1†), and
SAHA as internal control against the full panel of recombinant
human HDACs 1–11 applying a single inhibitor concentration
(ESI, Fig. S1†). The linear peptide was included to address the
importance of the macrocyclic nature of the azumamides and,
somewhat expectedly, the linear compound was not inhibiting
any of the HDACs potently. Poor inhibitory activities were also
observed for macrocycle 9 against class I HDAC8, class IIa
HDACs (4, 5, 7, and 9), and class IIb HDAC6, and it was there-
fore decided to proceed with full dose–response proling only
against HDACs 1–3, 10, and 11 (ESI, Fig. S2†).
To be able to compare potencies irrespective of applied
substrate identity and concentration in the assays, we deter-
mined Ki-values using the Cheng–Prusoﬀ equation34 and the
Km-values for the selected substrate–enzyme combinations
(Table 1).29,35,36 Not surprisingly, compound 9 was less potent
than its parent compound, azumamide C.
Still, compound 9 exhibited low micromolar inhibition of
class I HDACs evenwithout the ability to coordinate to Zn2+ in the
active site. Interestingly, the edited analogue (9) was either
equipotent or slightly more potent than the corresponding car-
boxamide-containing natural product azumamide B (Table 1 and
ESI, Fig. S2†). The azumamide core, however, could not compete
with the most potent compounds from the more elaborate series
Scheme 2 Reagents and conditions: (a) CuSO4 (5.0 equiv.), anhydrous
CH2Cl2, rt, 20 h; (b) tert-butyl propionate (2.5 equiv.), LDA (2.6 equiv.),
HMPA (5.7 equiv.), anhydrous THF, –78 C, 30 min; then imine 12; (c)
TFA–CH2Cl2 (1 : 1), rt, 5 h; (d) HCl (4.0 M in dioxane, 3.0 equiv.),
dioxane, rt, 1.5 h; (e) Na2CO3 (4.0 equiv.), Fmoc-OSu (1.2 equiv.), DMF–
H2O, 0 C/ rt, 3 h.
Scheme 3 Reagents and conditions: (a) HCl (4M in dioxane, 30 equiv.),
MeOH, rt, 22 h; (b) thionyl chloride (3.0 equiv.), MeOH, 0 C/ reﬂux,
23 h, then thionyl chloride (1.5 equiv.), MeOH, 0 C / rt, 22 h; (c)
EtOAc, saturated aqueous NaHCO3, benzylchloroformate, rt, 18 h.
Scheme 4 Macrolactamization to give compound 9 (7%, based on
resin loading).
Med. Chem. Commun. This journal is © The Royal Society of Chemistry 2014
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of cyclotetrapeptide HDAC inhibitors without Zn2+-binding
groups previously reported.24
Kinetic evaluation of HDACi activity
Since compound 9 was relatively potent against HDAC3 and
since HDAC3 was the only enzyme in complex with its co-
repressor,37 which may aﬀect the inhibitor potency,38 we chose
to investigate this interaction in more detail by kinetic experi-
ments. Performing progression curve inhibition experiments
where the enzymatic catalysis is followed over time in the
presence of various inhibitor concentrations may reveal
insights regarding the mechanism of inhibition. A recent study
demonstrated a slow-binding mechanism of benzamide-based
inhibitors against HDAC3-NCoR2,39 that would not be revealed
by simple dose–response experiments performed in an
endpoint fashion. We thus performed similar experiments to
investigate the mechanism of inhibition exhibited by both
azumamide C (6) and compound 9, with SAHA included as a
control compound (Fig. 1).
In all cases, the linear progression curves revealed a constant
rate of substrate conversion over time, which indicate a stan-
dard fast-on–fast-oﬀ mechanism of inhibition. This is in
agreement with previous ndings for SAHA39 and non-Zn2+-
binding macrocycles,24 but to the best of our knowledge, this is
the rst investigation of the mechanism of inhibition by azu-
mamide natural products.
The Ki-values derived from tting the continuous assay data
were generally 2–4-fold lower than those obtained by applying
the Cheng–Prusoﬀ equation to simple dose–response results
(Table 1). The respective values were in the same range,
however, and the relationship between compound potencies
showed the same trend. Thus, we nd the dose–response/
Cheng–Prusoﬀ method to be suﬃcient for determination of Ki-
values of compounds with a known fast-on–fast-oﬀ inhibition
mechanism.
Eﬀect on cultured cancer cells
Epigenetic silencing of the proapototic Bcl-2-family gene, Bim,
in Burkitt's lymphoma cells by concurrent promoter hyper-
methylation and deacetylation has been demonstrated to be
involved in the mechanism underlying the common chemo-
resistance of Burkitt's lymphoma. This chemoresistance has
been reversed by treatment with the HDAC inhibitor SAHA.40 To
investigate whether our compounds could inuence prolifera-
tion of lymphoma cells, we tested their eﬀect on the Epstein Barr
virus (EBV)-infected human Burkitt's lymphoma cell line, EB-3.
Table 1 Ki-values (mM) against HDAC isoforms from diﬀerent classes
a
Compd
Class I Class II Class IV
HDAC1 HDAC2 HDAC3b HDAC10 HDAC11
9 2.4  0.8 1.4  0.7 3.0  0.1 4  1 6  1
AzuB (5) 5c 3c 3c — >5c
AzuC (6) 0.02  0.01 0.01  0.006 0.018  0.001 0.02  0.005 0.06  0.008
SAHA 0.01  0.006 0.008  0.004 0.022  0.001 0.04  0.02 0.06  0.02
a Values were calculated from at least two individual dose–response experiments performed in duplicate using the Cheng–Prusoﬀ equation.
b Recombinant human HDAC3 was purchased as a complex with the deacetylase-activating domain of nuclear receptor co-repressor 2 (NCoR2).
c From a previous publication.29
Fig. 1 Progression curves and data ﬁtting of the inhibition of HDAC3-
NCoR2. Data were ﬁtted to the equation, vi/v0 ¼ (1 + [I]/(Ki(1 + [S]/
Km)))
1, using the GraphPad Prism software to derive the Ki-values
shown in the ﬁgure above.
This journal is © The Royal Society of Chemistry 2014 Med. Chem. Commun.
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To assess the eﬀects of azumamides B (5) and C (6) as well as
compound 9 along with positive controls SAHA and apicidin, we
used the MTT assay, in which cleavage of yellow MTT aﬀords
purple formazan crystals in functioning mitochondria to give a
measure of cell viability. Initially, we screened all ve
compounds in triplicate at 10 mM and only the positive controls,
SAHA and apicidin inhibited cell proliferation. We therefore
tested the compounds starting at higher concentrations of the
macrocycles. Since all compound stock solutions were prepared
in DMSO due to solubility issues, we tested 2-fold dilutions of
DMSO (from 1%) in parallel with the 2-fold serial dilutions of
the compounds. Based on this, SAHA and apicidin exhibited
GI50 values of 2.8 mM and 0.8 mM, respectively. For apicidin, this
correlates well with values previously obtained against HeLa,
Hct-116, MCF-7, KYO-1, and K-562 cells.23 The EB-3 cell prolif-
eration was inhibited at 1% but not at 0.5% DMSO and this
resulted in a maximal reliable concentration of azumamide C of
25 mM while it was 50 mM for azumamide B and 9. For all three
compounds the GI50 values were deemed well above this limit as
no reproducible growth inhibition was observed for any of the
compounds.
Conclusions
In the present study, we have synthesized an analogue of the
naturally occurring HDAC inhibitor, azumamide C, which is
structurally edited to prevent coordination to the zinc ion
present in the HDAC enzyme active sites. This allowed us to
elucidate the binding aﬃnity of the natural product's macro-
cyclic core, which proved to be in the low- to sub-micromolar
range. We furthermore, showed that both natural product and
its analogue inhibit HDAC3-NCoR2 via a fast-on–fast-oﬀ
mechanism by performing continuous assay experiments.
Not surprisingly, this non-Zn2+-binding analogue was
signicantly less potent than its carboxylate-containing parent
compound against HDACs. However, it is quite remarkable that
our synthetic analogue was at least as potent as the corre-
sponding carboxamide-containing natural product azumamide
B (5). It is puzzling that the marine sponge, from where the
natural products were originally isolated,26 produces these car-
boxamide-containing compounds that seem to adhere to the
general pharmacophore for HDAC inhibition, but apparently
contain a redundant Zn2+-binding group. We nally tested the
compounds' ability to inhibit proliferation of EB-3 cells in vitro.
Contrary to both SAHA and apicidin none of the tested azu-
mamide analogues were potent growth inhibitors, which
underscores that a ne-tuned combination of HDACi potency
and cell permeability is required for activity in cells.
Experimental
Synthetic procedures
(S,E)-N-Butylidene-2-methylpropane-2-sulnamide (12). A
solution of butyraldehyde (0.80 mL, 8.91 mmol, 2.0 equiv.) in
anhydrous CH2Cl2 (1.0 mL) was added dropwise to a solution of
anhydrous CuSO4 (3.6 g, 22.6 mmol, 5.0 equiv.) and (S)-()-2-
methyl-2-propanesulnamide (0.54 g, 4.46 mmol) in anhydrous
CH2Cl2 (7.0 mL). Aer stirring vigorously for 20 hours the
reaction mixture was ltered through a pad of Celite and the
lter cake washed with CH2Cl2. The combined organic phases
were concentrated in vacuo and purication by vacuum silica gel
chromatography aﬀorded tert-butanesulnyl imine 12 (0.72 g,
92%) as a colorless oil. 1H NMR (300 MHz, CDCl3) d 8.03 (t, J ¼
4.7 Hz, 1H), 2.46 (td, J¼ 7.3, 4.7 Hz, 2H), 1.63 (h, J¼ 7.4 Hz, 2H),
1.16 (s, 9H), 0.95 (t, J ¼ 7.4 Hz, 3H); 13C NMR (75 MHz, CDCl3) d
169.7, 56.5, 38.1, 22.5, 19.0, 13.9. Spectral data were in agree-
ment with previously reported data.41
(2S,3R)-tert-Butyl 3-((S)-1,1-dimethylethylsulnamido)-2-
methylhexanoate (13). A solution of LDA (1.5 M in THF, 5.0 mL,
7.5 mmol, 2.6 equiv.) was added dropwise over 5 min to a
solution of HMPA (1.5 mL, 8.6 mmol, 5.7 equiv.) in dry THF (5.0
mL) at 78 C. Aer 15 min, tert-butyl propionate (1.1 mL, 7.3
mmol, 2.5 equiv.) was added dropwise and aer stirring for
additionally 30 min imine 12 (0.51 g, 2.90 mmol) in anhydrous
THF (2.0 mL) was added dropwise. Aer 2 hours the reaction
was quenched with sat. aqueous NH4Cl and warmed to room
temperature. Aqueous HCl (1 M, 20 mL) was added and the
mixture extracted with EtOAc (2  60 mL). The combined
organic phases were washed with brine (40 mL), dried (MgSO4),
ltered, and concentrated in vacuo. Diastereoselectivity was
determined by 1H NMR integration of the crude reaction
mixture (65 : 25 : 8 : 2). Purication by silica gel chromatog-
raphy aﬀorded b-amino ester 13 (335 mg, 38%) as needle-like
crystals. 1H NMR (300 MHz, CDCl3) d 3.52 (m, 1H), 3.13 (d, J ¼
8.1 Hz, 1H), 2.46 (m, 1H), 1.60–1.46 (m, 3H), 1.42 (m, 10H), 1.18
(s, 9H), 1.07 (d, J¼ 7.1 Hz, 3H), 0.91 (t, J ¼ 6.9 Hz, 3H); 13C NMR
(75 MHz, CDCl3) d 173.8, 80.7, 59.0, 56.3, 45.2, 36.6, 28.2, 22.9,
19.4, 13.9, 11.8. HRMS (ESI-TOF) calcd for C15H31NO3H
+ [M +
H]+ 306.2103, found 306.2110.
(2S,3R)-3-Fmoc-amino-2-methylhexanoic acid (14). TFA (5.0
mL) was added to a solution of b-amino ester 13 (224 mg, 0.73
mmol) in anhydrous CH2Cl2 (5.0 mL). Aer 25 hours the reac-
tion mixture was concentrated and residual TFA was removed
by co-evaporation with toluene (3  10 mL). The resulting
residue was dissolved in dioxane (5.0 mL) and HCl in dioxane (4
M, 0.55 mL, 2.2 mmol, 3.0 equiv.) was added. Aer 1.5 hours the
mixture was concentrated. The crude fully deprotected b-amino
acid was suspended in water (5.0 mL) at 0 C and Na2CO3 (311
mg, 2.93 mmol, 4.0 equiv.) was added followed by Fmoc-O-
succinimide (297 mg, 0.88 mmol, 1.2 equiv.) in DMF (3.0 mL).
Cooling was removed and DMF (2.0 mL) was added. Aer 1.5
hours, water (5.0 mL) was added and aer additionally 1.5
hours of stirring the reaction mixture was diluted with water (60
mL) and extracted with Et2O (15 mL). Aer acidication with
concentrated HCl, until pH z 1–2, the aqueous layer was
extracted with EtOAc (3  75 mL). The combined organic pha-
ses were dried (MgSO4), ltered, and concentrated in vacuo.
Purication of the crude residue by vacuum silica gel chroma-
tography aﬀorded b-amino acid 14 (66 mg, 25%, 3 steps) as a
white solid aer co-evaporation of residual acetic acid with
CH2Cl2–toluene (1 : 1, 3  10 mL); 1H NMR (300 MHz, DMSO-
d6) d 12.19 (s, 1H), 7.86 (d, J ¼ 7.4 Hz, 2H), 7.66 (dd, J ¼ 7.3, 2.9
Hz, 2H), 7.38 (t, J ¼ 7.4 Hz, 2H), 7.30 (d, J ¼ 7.4, 2H), 7.05 (d, J ¼
9.5 Hz, 1H), 4.31 (m, 2H), 4.18 (t, J ¼ 6.7 Hz, 1H), 3.58 (m, 1H),
Med. Chem. Commun. This journal is © The Royal Society of Chemistry 2014
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2.28 (m, 1H), 1.22 (m, 4H), 0.95 (d, J¼ 6.9 Hz, 3H), 0.79 (t, J¼ 6.9
Hz, 3H); 13C NMR (75 MHz, DMSO-d6) d 176.2, 156.2, 143.9,
140.8, 127.6, 127.1, 127.0, 125.2 (2C), 120.1, 65.0, 52.4, 46.9,
44.4, 35.0, 18.8, 14.0, 13.7. HRMS (ESI-TOF) calcd for
C22H25NO4H
+ [M + H]+ 368.1862, found 368.1863.
(2S,3R)-Methyl 3-(((benzyloxy)carbonyl)amino)-2-methylhex-
anoate (15). HCl in dioxane (4 M, 4.7 mL, 18.8 mmol, 30 equiv.)
was added to a solution of b-amino ester 13 (190mg, 0.62mmol)
in MeOH (5.0 mL). Aer stirring for 22 hours the mixture was
concentrated. 1H NMR of the crude residue showed a mixture of
the fully deprotected b-amino acid and amine deprotected
methyl ester. To ensure full conversion to the methyl ester the
crude product was dissolved in MeOH (5.0 mL) under Ar, cooled
to 0 C, and thionyl chloride (70 mL, 0.94 mmol, 1.5 equiv.) was
added dropwise. Aer 10 min the reaction mixture was heated
under reux for 20 hours before additional thionyl chloride
(70 mL, 0.94 mmol, 1.5 equiv.) was added. Aer further 2.5 hours
of stirring the mixture was concentrated and redissolved in
MeOH (5.0 mL). Thionyl chloride (90 mL, 1.23 mmol, 2.0 equiv.)
was added at 0 C and the mixture stirred for 22 hours at room
temperature, before concentration aﬀorded the crude amine.
The crude amine was dissolved in sat. aqueous NaHCO3–EtOAc
(1 : 1, 6.0 mL) and benzylchloroformate (133 mL, 0.93 mmol, 1.5
equiv.) was added. Aer 18 hours of vigorous stirring the phases
were separated and the aqueous layer was diluted with water
(5 mL) and extracted with ethyl acetate (2  5 mL). The
combined organic phases were washed with aqueous HCl (1 M,
6 mL) and brine (6 mL), dried (Na2SO4), ltered, and concen-
trated in vacuo. Purication by vacuum silica gel chromatog-
raphy aﬀorded the b-amino ester 15 (37%, three steps from 13).
[a]20D 39 (CHCl3, c 1.0), previously reported [a]20D 34 (CHCl3,
c 1.0);32 1H NMR (400 MHz, CDCl3) d 7.38–7.28 (m, 5H), 5.09 (s,
2H), 4.95 (d, J¼ 9.7 Hz, 1H), 3.93–3.82 (m, 1H), 3.67 (s, 3H), 2.65
(m, 1H), 1.43 (m, 2H), 1.31 (m, 2H), 1.15 (d, J¼ 7.2 Hz, 3H), 1.15
(d, J ¼ 7.2 Hz, 3H); 13C NMR (100 MHz, CDCl3) d 175.0, 156.2,
136.7, 128.6, 128.2 (2C), 66.8, 53.2, 51.9, 44.1, 34.2, 19.6, 13.9,
13.2. The spectral data were in full accordance with those
reported in the literature (see ESI, Table S1†).32
Linear peptide 16. Polystyrene 2-chlorotrityl-bound Fmoc-D-
Val–D-Ala–D-Tyr (140 mg, 0.11 mmol) was added to a fritted
syringe and the Fmoc group was removed with piperidine–DMF
(1 : 4, 4 mL, 2  30 min) and DBU–piperidine–DMF (2 : 2 : 96, 4
mL, 30 min). The resin was then washed with DMF (3), MeOH
(3), and CH2Cl2 (3). b-Amino acid 14 (43 mg, 0.12 mmol, 1.1
equiv.) in DMF (2.0 mL) was preincubated for 5 min with 2,6-
lutidine (37 mL, 0.32 mmol, 3.0 equiv.) and HATU (61 mg, 0.16
mmol, 1.5 equiv.) before addition to the resin and the reaction
was allowed to proceed on a rocking table for 17 hours. Aer
washing with DMF (3), MeOH (3), and CH2Cl2 (3) the Fmoc
group was removed with piperidine–DMF (1 : 4, 4 mL, 2  30
min) and DBU–piperidine–DMF (2 : 2 : 96, 4 mL, 30 min). The
resin was then washed again and treated with TFA–CH2Cl2
(1 : 1, 4 mL) for 30 min followed by washing with CH2Cl2 (5 mL).
A fresh portion of TFA–CH2Cl2 (1 : 1, 4 mL) was added to the
resin and aer additional 30 min the resin was drained and all
the fractions were pooled and concentrated in vacuo to provide
the linear peptide as an oily residue. Trituration with diethyl
ether aﬀorded the TFA salt of the linear peptide 16 (53 mg, 81%
from 2-chlorotrityl chloride resin, based on theoretical loading
of resin) as a white solid. UPLC-MS, tR ¼ 0.84 min, calcd for
C24H38N4O6H
+ [M + H]+ 479.3, found 479.3; 1H NMR (400 MHz,
MeOD) d 7.04 (d, J ¼ 8.2 Hz, 2H), 6.69 (d, J ¼ 8.2 Hz, 2H), 4.58
(m, 1H), 4.38 (m, 1H), 4.15 (d, J ¼ 7.1 Hz, 1H), 3.38 (m, 1H), 3.07
(dd, J¼ 14.0, 5.3 Hz, 1H), 2.92 (dd, J¼ 14.0, 7.8 Hz, 1H), 2.79 (m,
1H), 2.05 (octet, J ¼ 6.9 Hz, 1H), 1.60 (q, J ¼7.8 Hz, 2H), 1.54–
1.39 (m, 2H), 1.33 (d, J ¼ 7.1 Hz, 3H), 1.21 (d, J ¼ 7.2 Hz, 3H),
0.99 (t, J ¼ 7.3 Hz, 3H), 0.93 (d, J ¼ 6.8 Hz, 6H).
Cyclic peptide 9. Linear peptide 16 (50 mg, 0.084 mmol) was
dissolved in DMF (200 mLz 0.4 mM) and iPr2NEt (73 mL, 0.42
mmol, 5.0 equiv.) and HATU (48mg, 0.13mmol, 1.5 equiv.) were
added. Aer stirring for 19 hours the reaction mixture was
concentrated in vacuo. The residue was taken up in CH2Cl2
(80 mL) and washed with aqueous HCl (1 M, 2 15 mL) and the
aqueous phase was re-extracted with CH2Cl2 (50 mL). The
combined organics were washed with brine (25 mL), dried
(MgSO4), ltered, and concentrated in vacuo. The resulting
residue was dissolved in DMF (2.5 mL) and puried by
preparative HPLC on a [250 mm  20 mm, C18 Phenomenex
Luna column (5 mm, 100 A˚)] using an Agilent 1260 LC system to
aﬀord the cyclic peptide 9 (2.7 mg, 7%) as a white solid. A
gradient with eluent III (95 : 5 : 0.1, water–MeCN–TFA) and
eluent IV (0.1% TFA in acetonitrile) rising linearly from 0% to
95% of eluent IV during t ¼ 5–45 min was applied at a ow rate
of 20 mL min1. Two conformations are observed in the 1H
NMR spectrum. The conformations are present in an 88 : 12
ratio. Characterization is given for the major conformation. 1H
NMR (500 MHz, DMSO-d6) d 9.19 (br s, 1H), 7.67 (d, J ¼ 8.8 Hz,
1H), 7.55 (d, J ¼ 9.0 Hz, 1H), 7.46 (d, J ¼ 8.4 Hz, 1H), 6.96 (m,
3H), 6.63 (d, J ¼ 8.4 Hz, 2H), 4.14 (p, J ¼ 7.3 Hz, 1H), 4.07 (p, J ¼
8.8 Hz, 1H), 3.99 (m, 1H), 3.67 (t, J ¼ 9.4 Hz 1H), 2.89 (dd, J ¼
13.7, 7.2 Hz, 1H), 2.81 (dd, J ¼ 13.7, 9.0 Hz, 1H), 2.54 (m, 1H),
2.16 (m, 1H), 1.64 (m, 1H), 1.36 (m, 1H), 1.25–1.15 (m, 8H), 0.91–
0.77 (m, 9H); HRMS (ESI-TOF) calcd for C24H36N4O5H
+ [M + H]+
461.2719, found 461.2754; HPLC gradient B, tR ¼ 11.14 min
(>95%).
Biochemical proling
In vitro histone deacetylase inhibition assays. For assaying,
peptides were reconstituted in DMSO to give 5–10 mM stock
solutions, the accurate concentrations of which were deter-
mined by UV using the extinction coeﬃcient for tyrosine at 280
nm; 3 ¼ 1280 M1  cm1. Inhibition of recombinant human
HDACs in dose–response experiments with internal controls
was measured in black low binding Corning half-area 96-well
microtiter plates. The appropriate dilution of inhibitor (5 mL of
5 the desired nal concentration, prepared from 5–10 mM
DMSO stock solutions) was added to each well followed by
substrate in HDAC assay buﬀer (10 mL). Ac–Leu–Gly–Lys (Ac)–
AMCwas used at a nal concentration of 20 mM for HDAC1, 2, 3,
6, and 11. Ac–Leu–Gly–Lys (Tfa)–AMC was used at a nal
concentration of 20 mM for HDAC4, 120 mM for HDAC5, 40 mM
for HDAC7 and 200 mM for HDAC8, and 80 mM for HDAC9. Ac–
Arg–His–Lys (Ac)–Lys (Ac)–AMC was used at a nal
This journal is © The Royal Society of Chemistry 2014 Med. Chem. Commun.
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concentration of 5 mM for HDAC10. Finally, a freshly prepared
solution of the appropriate HDAC (10 mL) was added and the
plate (containing a nal volume of 25 mL in each well) was
incubated at 37 C for 30 min. The nal concentrations of
enzyme was as follows: HDAC1: 1 ng mL1, HDAC2: 0.5 ng mL1,
HDAC3-NCoR2: 0.09 ng mL1, HDAC4: 0.04 ng mL1, HDAC5: 0.2
ng mL1, HDAC6: 2.4 ng mL1, HDAC7: 0.04 ng mL1, HDAC8: 0.2
ng mL1, HDAC9: 0.8 ng mL1, HDAC10: 4 ng mL1, HDAC11: 10
ng mL1. Then trypsin (25 mL, 0.4 mg mL1) was added and the
assay development was allowed to proceed for 15–30 min at
room temperature, before the plate was read using a Perkin
Elmer Enspire plate reader with excitation at 360 nm and
detecting emission at 460 nm. Each assay was performed in
duplicate and repeated at least twice. The data were analyzed by
non-linear regression using GraphPad Prism to aﬀord IC50
values from the dose–response experiments, and Ki values were
determined from the Cheng–Prusoﬀ equation, Ki¼ IC50/(1 + [S]/
Km), assuming a standard fast-on–fast-oﬀ mechanism of inhi-
bition. The applied Km values were previously reported for
HDACs 1–3,35 HDAC10,29 and HDAC11.36
Continuous assay protocol. The continuous assays of
HDAC3-NCoR2 inhibition were performed in 96-well, white,
medium binding, half-area microtiter plates (Greiner Bio One).
The 2- or 3-fold dilution series of inhibitors were prepared as
described above. HDAC assay buﬀer (10 mL) containing
substrate Ac–Leu–Gly–Lys (Ac)–AMC (100 mM; nal concentra-
tion 20 mM) and HDAC assay buﬀer (10 mL) containing trypsin
(12.5 ng mL1; nal concentration 2.5 ng mL1) was added to
each well, followed by the appropriate dilution of inhibitor (20
mL of 2.5 the desired nal concentration). Finally, a solution of
HDAC3-NCoR2 (10 mL, 0.2 ng mL1 ¼ 2.5 nM; nal concentra-
tion 0.04 ng mL1 ¼ 0.5 nM) was added, and uorescence
readings were recorded every 30 seconds for 45 min at 25 C
using a Perkin Elmer Enspire plate reader with excitation at 360
nm and detecting emission at 460 nm. Each assay was per-
formed twice in duplicate. The rate constants (v) were deter-
mined by linear regression analysis using GraphPad Prism. Ki
values were then determined by non-linear tting to the
following equation, vi/v0 ¼ (1 + [I]/(Ki(1 + [S]/Km)))1.
In vitro cell proliferation assay. Cell proliferation was assessed
using theMTT cell growth kit (Millipore, Billerica, MA, USA). EB-3
cells (ATCC, Manassas, VA, USA) were seeded in 96-well at-
bottom cell culture plates (Nunc, Thermo Fischer Scientic,
Roskilde, Denmark) with a density of 2  104 cells in 90 mL
culture media composed of RPMI-1640 (ATCC, Manassas, VA,
USA) supplemented with 10% fetal calf serum (FCS) (Sera Scan-
dia, Hellerup, Denmark) and 1% penicillin/streptomycin (Gibco,
Invitrogen, Taastrup, Denmark). Aer cultivation overnight at 37
C in humid 5% CO2 atmosphere, 10 mL of culture medium
containing appropriate concentrations of the ve compounds or
the vehicle (DMSO) as control were added. The 2-fold dilution
series were prepared from DMSO stock solutions (5 mM for
azumamide C and 10 mM for the remaining compounds) to give
nal assay concentrations starting from 50 mM for azumamide C,
SAHA, and apicidin while 100 mM was applied for azumamide B
and compound 9. Aer incubation for 3 days, MTT solution was
freshly prepared by dissolving 3-(4,5-dimethylthiazol-2-yl)-2,5-
diphenyltetrazolium bromide (MTT, 50 mg) in PBS (10 mL, both
supplied in the MTT assay kit) and 10 mL of this solution was
added to each well. The cells were incubated for another 4 h at
37 C in humid 5% CO2 atmosphere for development to take
place. The purple formazan crystals produced were dissolved by
addition of isopropyl alcohol (100 mL per well) containing HCl
(0.04 M), and the absorbance was measured at 570 nm with
background subtraction at 630 nm on a Tecan Sunrise ELISA
plate reader (Tecan, Switzerland). All assays were performed three
times in duplicate.
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General Experimental 
Materials and methods. All chemicals and solvents were analytical grade and used without further purification. 
Vacuum liquid chromatography (VLC) was performed on silica gel 60 (particle size 0.015−0.040µm). 
UPLC−MS analyses were performed on a Waters Acquity ultra high-performance liquid chromatography 
system. A gradient with eluent I (0.1% HCOOH in water) and eluent II (0.1% HCOOH in acetonitrile) rising 
linearly from 0% to 95% of II during t = 0.00–2.50 min was applied at a flow rate of 1 mL/min. Analytical 
HPLC was performed on a [150 mm × 4.6 mm, C18 Phenomenex Luna column (3 µm)] using an Agilent 1100 
LC system equipped with a UV detector. A gradient, B, with eluent III (95:5:0.1, water−MeCN−TFA) and eluent 
IV (0.1% TFA in acetonitrile) rising linearly from 0% to 95% of IV during t = 2−20 min was applied at a flow 
rate of 1 mL/min. Preparative reversed-phase HPLC was performed on a [250 mm × 20 mm, C18 Phenomenex 
Luna column (5 µm, 100 Å)] using an Agilent 1260 LC system equipped with a diode array UV detector and an 
evaporative light scattering detector (ELSD). A gradient C with eluent III (95:5:0.1, water−MeCN−TFA) and 
eluent IV (0.1% TFA in acetonitrile) rising linearly from 0% to 95% of IV during t = 5−45 min was applied at a 
flow rate of 20 mL/min. 1D and 2D NMR spectra were recorded on a Varian INOVA 500 MHz instrument, a 
Bruker Ascend 400 MHz or a Varian Mercury 300 instrument. All spectra were recorded at 298 K. For the 
Varian INOVA 500 MHz instrument and the Varian Mercury 300 instrument 1D NMR spectra were recorded at 
499.9 MHz and 300 MHz for 1H and 100 MHz and 75 MHz for 13C, respectively.  The correlation spectroscopy 
(COSY) spectra were recorded with a relaxation delay of 1.5 sec before each scan, a spectral width of 6k × 6k, 
collecting 8 FIDs and 1k × 512 data points. Heteronuclear single quantum coherence (HSQC) spectra were 
recorded with a relaxation delay of 1.5 sec before each scan, a spectral width of 6k × 25k, collecting 16 FIDs and 
1k × 128 data points. Heteronuclear 2-bond correlation (H2BC) spectra were recorded with a relaxation delay of 
1.5 sec before each scan, a spectral width of 4k × 35k, collecting 16 FIDs at 295 K and 1k × 256 datapoints. 
Heteronuclear multiple-bond correlation (HMBC) spectra were recorded with a relaxation delay of 1.5 sec 
before each scan, a spectral width of 6k × 35 k, collecting 32 FIDs and 1k × 256 datapoints. Finally, on the 
Bruker Ascend 400 MHz the 1D NMR spectra were recorded at 400 MHz for 1H and 100 MHz for 13C. The 
correlation spectroscopy (COSY) spectra were recorded with a relaxation delay of 1.5 sec before each scan, a 
spectral width of 3k × 3k, collecting 4 FIDs and 1k × 128 data points. The heteronuclear single quantum 
coherence (HSQC) spectra were recorded with a relaxation delay of 1.5 sec before each scan, a spectral width of 
4800 × 16600, collecting 4 FIDs and 1k × 256 datapoints.  Chemical shifts are reported in ppm relative to 
deuterated solvent peaks as internal standards (δH, DMSO-d6 2.50 ppm; δC, DMSO-d6 39.52 ppm, δH, CDCl3 
7.26 ppm; δC, CDCl3 77.16 ppm). Coupling constants (J) are given in hertz (Hz). Multiplicities of 1H NMR 
signals are reported as follows: s, singlet; d, doublet; t, triplet; q, quartet; m, multiplet. 
	  	   S3	  
Assay materials. HDAC1 (Purity ≥62% by SDS-PAGE according to the supplier), HDAC2 (Full length, purity 
≥94% by SDS-PAGE according to the supplier), HDAC3-NCoR2 complex (Purity ≥80% by SDS-PAGE 
according to supplier, HDAC4 (Purity ≥60% by SDS-PAGE according to the supplier) and HDAC 5 (Full 
length, purity ≥90% by SDS-PAGE according to the supplier), HDAC8 (Purity ≥90% by SDS-PAGE according 
to the supplier), HDAC9 (Full length, purity ≥76% by SDS-PAGE according to the supplier) and HDAC10 
(Purity ≥21% by SDS-PAGE according to the supplier) were purchased from BPS Bioscience (San Diego, CA 
92121). HDAC 7 (Purity ≥90% by SDS-PAGE according to the supplier) was purchased from Millipore 
(Temecula, CA 92590). HDAC6 (Purity ≥85% by SDS-PAGE according to the supplier) and HDAC11 (Purity 
≥50% by SDS-PAGE according to the supplier) were purchased from Enzo Life Sciences (Postfach, 
Switzerland). The HDAC assay buffer (50 mM tris/Cl, pH 8.0, 137 mM NaCl, 2.7 mM KCl, 1 mM MgCl2) was 
added bovine serum albumin (0.5 mg/mL). Trypsin (10,000 units/mg, TPCK treated from bovine pancreas) was 
from Sigma Aldrich (Steinheim, Germany). All peptides were purified to homogeneity (>95% purity by 
HPLC230nm using reversed-phase preparative HPLC), and the white fluffy materials obtained by lyophilization 
were kept at –20 °C. 
 
Table S1. Comparison of 1H and 13C NMR data for reference and compound 15 
Position 1H MacMillana 13C MacMillan 1H Compound 15 13C Compd. 15 
1  174.9  175.0 
2 2.71–2.62 (m, 1H) 43.9 2.65 (m, 1H) 44.1 
3 3.94–3.84 (m, 1H) 53.0 3.93–3.82 (m, 1H) 53.2 
4 1.50–1.38 (m, 2H) 34.0 1.43 (m, 2H) 34.2 
5 1.38–1.25 (m, 2H) 19.4 1.31 (m, 2H) 19.6 
6 0.92 (bt, J = 6.6 Hz, 3H) 13.8 1.15 (d, J = 7.2 Hz, 3H) 13.9 
OMe 3.58 (s, 3H) 51.8 3.67 (s, 3H) 51.9 
α-Me 1.17 (d, J = 7.2 Hz, 3H) 13.1 1.15 (d, J = 7.2 Hz, 3H) 13.2 
Ar 7.41–7.30 (m, 5H) 136.5; 128.5; 
128.1×2;  
7.38 –7.28 (m, 5H) 136.7; 128.6; 
128.2×2;  
PhCH2 5.10 (s, 2H) 66.7 5.09 (s, 2H) 66.8 
NH 4.93 (d, J = 9.5 Hz, 1H)  4.95 (d, J = 9.7 Hz, 1H)  
Carbamate  156.0  156.2 
a Ref 32, J. E. Wilson, A. D. Casarez and D. W. MacMillan, J. Am. Chem. Soc., 2009, 131, 11332-11334. 
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Figure S1. Single-dose HDAC inhibition experiments.a 
 
aWith SAHA (vorinostat) as control compound, we tested the ability of compound 9 as well as the shown linear 
azumamide C analogue (C) to inhibit all the zinc-dependent recombinant human HDAC enzymes at 10 µM (A) 
and 100 µM concentrations (B), respectively. *HDAC3 was applied as a complex with NCoR2.  
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Figure S2. Dose-response HDAC inhibition experiments.a 
 
aWith SAHA (vorinostat) as internal control compound in all assay plates, we performed dose-response 
experiments in at least two individual assays performed in duplicate. Data for Azumamide B are taken from a 
previous publication (ref 29, J. S. Villadsen, H. M. Stephansen, A. R. Maolanon, P. Harris, and C. A. Olsen, J. 
Med. Chem., 2013, 56, 6512-6520) Data were analyzed and plotted using the GraphPad Prism software. 
*HDAC3 was applied as a complex with NCoR2.  
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